Postmenopausal Osteoporosis Treatment Market Size - By Drug Type (Bisphosphonates, Hormone Replacement Therapy (HRT)), Route of Administration, Distribution Channel, Global Forecast (2023-2032)

Description

List of Tables

Postmenopausal Osteoporosis Treatment Market size is estimated to depict 4.6% CAGR from 2023 to 2032 attributed to the surge in supportive government initiatives and healthcare policies worldwide. The influx of subsidized healthcare services, medication affordability, and supportive R&D initiatives are creating an environment conducive to effective osteoporosis management. Additionally, there has been significant increase in government-driven regulations and guidelines for ensuring quality standards and patient safety while promoting the integration of innovative treatment approaches.

Furthermore, the rising efforts by industry players on strengthening their market position through the development of advanced generic formulations and device engineering to enhance patient access to crucial treatment options will augment the industry outlook. For instance, in November 2023, Teva Pharmaceuticals Inc., a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. received approval to market the generic version of Forteo®1, an injectable containing teriparatide, prescribed to treat osteoporosis in certain male and female patients.

The postmenopausal osteoporosis treatment industry is segmented into drug type, route of administration, distribution channel, and region.

Based on drug type, the market share from the hormone replacement therapy (HRT) segment is anticipated to gain 4.8% CAGR between 2023 and 2032. HRT has emerged as an effective treatment approach for postmenopausal osteoporosis as it helps to maintain bone density, reduce fracture risk, and manage symptoms. Additionally, the increasing adoption of hormone replacement therapies to treat postmenopausal women coupled with the ongoing R&D efforts for formulations will propel the segment expansion.

In terms of distribution channel, the postmenopausal osteoporosis treatment industry from the hospital pharmacies segment is estimated to record 3.7% growth rate through 2032. Hospital pharmacies serve as crucial distribution points for osteoporosis medications for ensuring accessibility to prescribed treatments. The convenience of obtaining medications from hospital pharmacies and the higher availability of expert healthcare professionals at hospitals will contribute to the segment growth.

Regionally, the Asia Pacific postmenopausal osteoporosis treatment market is set to exhibit 5.2% growth rate through 2032 driven by the aging population and increasing awareness of osteoporosis management. According to NCBI estimations published in 2023, Asia will account for more than half of all fractures caused by osteoporosis by 2050, with postmenopausal women being the most vulnerable. This rising prevalence of osteoporosis among postmenopausal women across the region is expected to fuel the demand for advanced therapies. Moreover, the rising healthcare expenditure, improving healthcare infrastructure, and government initiatives will further boost the adoption of postmenopausal osteoporosis treatments in the region.

Product Code: 7186

Chapter 1 Methodology & Scope

1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast Calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Postmenopausal osteoporosis treatment industry 360 degree synopsis, 2018 - 2032 (USD Million)
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Drug type trends
- 2.1.4 Route of administration trends
- 2.1.5 Distribution channel trends

Chapter 3 Postmenopausal Osteoporosis Treatment Market Insights

3.1 Industry landscape, 2018 - 2032 (USD Million)
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of osteoporosis among elderly woman population
  - 3.2.1.2 Rising R&D and new drug approvals
  - 3.2.1.3 Government initiatives
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Treatment compliance
  - 3.2.2.2 Adverse effects of medications
- 3.2.3 Growth potential analysis
- 3.2.4 By drug type
- 3.2.5 By route of administration
- 3.2.6 By distribution channel
3.3 COVID-19 impact analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022

Chapter 5 Postmenopausal Osteoporosis Treatment Market Estimates and Forecast, By Drug Type, 2018-2032 (USD Million)

5.1 Key trends, by drug type
5.2 Bisphosphonates
5.3 Hormone replacement therapy (HRT)
5.4 Parathyroid hormone
5.5 Estrogen receptor modulators
5.6 Other drug types

Chapter 6 Postmenopausal Osteoporosis Treatment Market Estimates and Forecast, By Route of Administration, 2018-2032 (USD Million)

6.1 Key trends, by route of administration
6.2 Oral
6.3 Parenteral
6.4 Transdermal
6.5 Nasal

Chapter 7 Postmenopausal Osteoporosis Treatment Market Estimates and Forecast, By Distribution Channel, 2018-2032 (USD Million)

7.1 Key trends, by distribution channel
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Online Pharmacies

Chapter 8 Postmenopausal Osteoporosis Treatment Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East & Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 Rest of Middle East & Africa

Chapter 9 Company Profiles

9.1 Eli Lilly and Company
9.2 Merck Sharp & Dohme Corp. (Merck & Co., Inc.)
9.3 AbbVie company (Allergan Pharmaceuticals International Ltd.)
9.4 Amgen Inc.
9.5 Theramex(PAI and Carlyle)
9.6 Sun Pharmaceutical Industries Ltd.
9.7 Pfizer Inc.
9.8 Novartis AG
9.9 Mylan Inc.
9.10 Chugai Pharma China Co., Ltd. (Roche)